Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Connect Twitter with Market Wire News

CLRB - Cellectar Biosciences Stock Trading


home / stock / clrb

CLRB CLRB Quote CLRB Short CLRB News CLRB Articles CLRB Message Board

About | Cellectar Biosciences Inc. (NASDAQ:CLRB)

Cellectar Biosciences is developing agents to detect, treat and monitor a broad spectrum of cancers. Utilizing a novel phospholipid ether PLE platform technology as a targeted delivery and retention vehicle, Cellectar s compounds are designed to be selectively taken up and retained in both cancer cells and cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Cellectar has developed a portfolio of product candidates engineered to capitalize on the unique characteristics of cancer cells to find, treat and follow malignancies in a highly selective way. I CLR is a small molecule, broad spectrum, cancer targeted PET imaging agent. A Phase II trial evaluating I CLR in glioblastoma is expected to be completed in . Additionally multiple, investigator sponsored Phase I/II clinical trials are ongoing across solid tumor indications. I CLR is a small molecule, broad spectrum, cancer targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. Data from a Phase Ib dose escalation trial of I CLR in patients with advanced solid tumors is anticipated in the first quarter of . CLR is a preclinical, cancer targeted, non radioactive optical imaging agent for intraoperative tumor margin illumination and non invasive tumor imaging. For additional information please visit www.cellectar.com

Quote | Cellectar Biosciences Inc. (NASDAQ:CLRB)

Last:$1.835
Change Percent: -0.01%
Open:$1.7601
Close:$1.835
High:$1.84
Low:$1.7601
Volume:14,009
Last Trade Date Time:06/09/2023 03:00:00 am

News | Cellectar Biosciences Inc. (NASDAQ:CLRB)

  • Cellectar Biosciences GAAP EPS of -$0.76

    2023-05-04 10:10:06 ET Cellectar Biosciences press release ( NASDAQ: CLRB ): Q1 GAAP EPS of -$0.76. As of March 31, 2023, the company had cash and cash equivalents of $12.7 million, compared to $19.9 million as of December 31, 2023. For further details see: ...

    • May 04, 2023 10:10:06 am
    • |
    • SeekingAlpha
    • |
      • CLRB Stock
      • CLRB Quote
      • CLRB Short
      • CLRB News
      • CLRB Articles
      • CLRB Message Board
  • UPDATE -- Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update

    FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the first quarter ended...

    • May 04, 2023 09:22:59 am
    • |
    • GlobeNewswire
    • |
      • CLRB Stock
      • CLRB Quote
      • CLRB Short
      • CLRB News
      • CLRB Articles
      • CLRB Message Board

Message Board Posts | Cellectar Biosciences Inc. (NASDAQ:CLRB)

Subject By Source When
whytestocks: $CLRB News Article - Cellectar Reports Financial Results for First Quarter 2023 and Pro whytestocks investorshangout 05/04/2023 12:55:45 PM
whytestocks: $CLRB News Article - Cellectar Biosciences Reports Complete Response in a Relapsed/Refr whytestocks investorshangout 02/28/2023 4:40:48 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Source:Edgar (US abracky investorshub 12/12/2022 5:44:16 AM
Look at $PSTV - All the due diligence The Ultimate Choice investorshub 09/06/2022 1:47:38 PM
whytestocks: $CLRB News Article - Cellectar Reports Financial Results for Second Quarter 2022 whytestocks investorshangout 08/05/2022 5:01:10 PM
Stock Information

Cellectar Biosciences Inc. Company Name:

CLRB Stock Symbol:

NASDAQ Market:

Cellectar Biosciences Inc. Website:

Cellectar Biosciences Inc. Logo

Get CLRB Alerts

News, Short Squeeze, Breakout and More Instantly...

Ad

Connect Twitter with Market Wire News
RECENT CLRB NEWS
  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Coins
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your Twitter Account

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.



Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.

WATCH LIVE TRENDING STOCKS

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

Follow @marketwirenews

| Facebook

| Telegram

| LinkedIn

| Reddit

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2023 Market Wire News